Phospho-EGFR (Tyr1068) (E5) rabbit mAb

www.abwizbio.com
Support: info@abwizbio.com
Order: sales@abwizbio.com

Catalog: #2081

Store at: -20ºC

For Research Use Only. Not For Use In Diagnostic Procedures.

Applications	Detection	Clonality	Isotype
Flow Cytometry	Anti-Rabbit IgG	Monoclonal	Rabbit IgGk

Format: Unconjugated

Cross Reactivity: Predicted to work with mouse, rat and other homologues.

Formulation: 1X PBS, 0.02% NaN3, 50% Glycerol, 0.1% BSA

Preparation: Protein A+G

Reactivity: Human,Mouse,Rat

Recommended Usage: 1µg/mL – 0.001µg/mL. It is recommended that the reagent be titrated for optimal performance for each application. See product image legends for additional information.

Immunogen: A synthetic phospho-peptide corresponding to residues surrounding Tyr1068 of human phospho EGFR.

Description: The epidermal growth factor receptor (EGFR; ErbB-1; HER1 in humans) is a transmembrane protein that is a receptor for members of the epidermal growth factor family (EGF family) of extracellular protein ligands (1). EGFR (rbB-1) is closely related to other members of the ErbB family of receptors: HER2/neu(ErbB-2), HER3 (ErbB-3) and HER4 (ErbB-4). In many cancer types, mutations affecting EGFR expression or activity could result in cancer (2). Overexpression of EGFR is associated with the development of a wide variety of tumors. Interruption of EGFR signaling, either by blocking EGFR binding sites on the extracellular domain of the receptor or by inhibiting intracellular tyrosine kinase activity, can prevent the growth of EGFR-expressing tumors and improve the patient's condition. EGFR is activated by the binding of its ligands including EGF and dimerization stimulates its intrinsic intracellular protein-tyrosine kinase activity. Activation of EGFR leads to autophosphorylation of tyrosine (Tyr) residues; Tyr992, Tyr1045, Y1068, Tyr1148, and Tyr1173 in the C-terminal domain.

References:

(1) Herbst RS (2004). "Review of epidermal growth factor receptor biology". International Journal of Radiation Oncology, Biology, Physics. 59 (2 Suppl): 21–6.
(2) Zhang H, Berezov A, Wang Q, Zhang G, Drebin J, Murali R, Greene MI (August 2007). "ErbB receptors: from oncogenes to targeted cancer treatment". The Journal of Clinical Investigation. 117 (8): 2051–8.



Flow cytometric analysis of C6 cells secondary antibody only (blue) treated with imatinib (grey) with 0.1 µg/mL of isotype control Cat. #2141 or imatinib (red) or pervanadate (green) using 0.1 µg/mL of Phospho-EGFR (Tyr1068) antibody EGFRY1068-E5 (green) Cat. #2081.



Flow cytometric analysis of HeLa cells secondary antibody only (blue) treated with imatinib (grey) or pervanadate (orange) with 0.1 µg/mL of isotype control Cat. #2141 or imatinib (red) or pervanadate (green) using 0.1 µg/mL of Phospho-EGFR (Tyr1068) antibody EGFRY1068-E5 (green) Cat. #2081.



Flow cytometric analysis of 3T3 cells secondary antibody only (blue) treated with imatinib (grey) or pervanadate (orange) with 0.1 µg/mL of isotype control Cat. #2141 or imatinib (red) or pervanadate (green) using 0.1 µg/mL of Phospho-EGFR (Tyr1068) antibody EGFRY1068-E5 (green) Cat. #2081.



	SampleID	Median : BL1-A
☐	Pv E5 N	8382
☐	Imatinib E5 N	1735
☐	Pv E5 P	1421
☐	Imatinib E5 P	1222
☐	Pv E5	8123
☐	Imatinib E5	1727
☐	Imatinib 2' only	521

Peptide blocking flow cytometric analysis of HeLa cells secondary antibody only negative control (light blue) or treated with imatinib (red) or with pervanadate (green) or imatinib and blocked with phospho-peptide (black) or pervanadate and blocked with phospho peptide (gold) or imatinib and blocked with non-phospho peptide (dark blue) or pervanadate and blocked with non-phospho peptide (purple) using Phospho-EGFR (Tyr1068) antibody EGFRY1068-E5 at 0.01µg/mL. Cat. #2081.



Flow cytometric analysis of K562 cells secondary antibody only negative control (blue) or untreated (red) or treated with EGF and pervanadate (green) using Phospho-EGFR (Tyr1068) antibody at 0.01 µg/mL EGFRY1068-E5. Cat. #2081.



Flow cytometric analysis of 3T3 cells secondary antibody only (blue) treated with imatinib (grey) or pervanadate (orange) with 0.1 µg/mL of isotype control Cat. #2141 or imatinib (red) or pervanadate (green) using 0.1 µg/mL of Phospho-EGFR (Tyr1068) antibody EGFRY1068-E5 (Abwiz Cat. #2081) or Company C antibody at 0.5ug/mL (suggested concentration by the manufacturer).